{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:07:43Z","timestamp":1784012863782,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Kimura Foundation for Nursing Education","award":["FY2017"],"award-info":[{"award-number":["FY2017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00520-026-10902-9","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:06:45Z","timestamp":1782230805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of hydrocolloid dressing for hand-foot skin reaction: J-SUPPORT 1701 APRON trial"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8180-195X","authenticated-orcid":false,"given":"Asako","family":"Ryu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadamoto","family":"Zenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuo","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Tsutsumida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoe","family":"Mashiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tempei","family":"Miyaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"10902_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312. https:\/\/doi.org\/10.1016\/S0140-6736(12)61900-X","journal-title":"Lancet"},{"key":"10902_CR2","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s10637-014-0154-x","volume":"33","author":"T Yoshino","year":"2015","unstructured":"Yoshino T, Komatsu Y, Yamada Y et al (2015) Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Invest New Drugs 33:740\u2013750. https:\/\/doi.org\/10.1007\/s10637-014-0154-x","journal-title":"Invest New Drugs"},{"key":"10902_CR3","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/jjco\/hym095","volume":"37","author":"H Akaza","year":"2007","unstructured":"Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S (2007) Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37:755\u2013762. https:\/\/doi.org\/10.1093\/jjco\/hym095","journal-title":"Jpn J Clin Oncol"},{"key":"10902_CR4","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","volume":"23","author":"D Strumberg","year":"2005","unstructured":"Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965\u2013972. https:\/\/doi.org\/10.1200\/JCO.2005.06.124","journal-title":"J Clin Oncol"},{"key":"10902_CR5","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1158\/1078-0432.CCR-11-1900","volume":"18","author":"K Mross","year":"2012","unstructured":"Mross K, Frost A, Steinbild S et al (2012) A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18:2658\u20132667. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1900","journal-title":"Clin Cancer Res"},{"key":"10902_CR6","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","volume":"26","author":"B McLellan","year":"2015","unstructured":"McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E (2015) Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol 26:2017\u20132026. https:\/\/doi.org\/10.1093\/annonc\/mdv244","journal-title":"Ann Oncol"},{"key":"10902_CR7","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","volume":"13","author":"ME Lacouture","year":"2008","unstructured":"Lacouture ME, Wu S, Robert C et al (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13:1001\u20131011. https:\/\/doi.org\/10.1634\/theoncologist.2008-0131","journal-title":"Oncologist"},{"key":"10902_CR8","first-page":"e61","volume":"11","author":"B Nardone","year":"2012","unstructured":"Nardone B, Hensley JR, Kulik L et al (2012) The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol 11:e61\u2013e65","journal-title":"J Drugs Dermatol"},{"key":"10902_CR9","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1200\/JCO.2013.52.9651","volume":"33","author":"ZG Ren","year":"2015","unstructured":"Ren ZG, Zhu KS, Kang HY et al (2015) Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 33:894\u2013900. https:\/\/doi.org\/10.1200\/JCO.2013.52.9651","journal-title":"J Clin Oncol"},{"issue":"7","key":"10902_CR10","doi-asserted-by":"publisher","first-page":"e1532","DOI":"10.1002\/cnr2.1532","volume":"5","author":"RY Lien","year":"2022","unstructured":"Lien RY, Tung HH, Wu SL (2022) Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: a randomised experiment study. Cancer Rep 5(7):e1532. https:\/\/doi.org\/10.1002\/cnr2.1532","journal-title":"Cancer Rep"},{"issue":"3","key":"10902_CR11","doi-asserted-by":"publisher","first-page":"102073","DOI":"10.1016\/j.clgc.2024.102073","volume":"22","author":"SS Naeem","year":"2024","unstructured":"Naeem SS, Gupta P, Sahoo RK et al (2024) A randomized, double-blind, placebo-controlled trial evaluating the effect of topical urea for secondary prophylaxis of hand foot skin reaction in renal cell cancer patients on sunitinib therapy. Clin Genitourin Cancer 22(3):102073. https:\/\/doi.org\/10.1016\/j.clgc.2024.102073","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"10902_CR12","doi-asserted-by":"publisher","first-page":"8655","DOI":"10.1007\/s00520-022-07175-3","volume":"30","author":"JGP Pandy","year":"2022","unstructured":"Pandy JGP, Franco PIG, Li RK (2022) Prophylactic strategies for hand\u2013foot syndrome\/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials. Support Care Cancer 30(11):8655\u20138666. https:\/\/doi.org\/10.1007\/s00520-022-07175-3","journal-title":"Support Care Cancer"},{"key":"10902_CR13","first-page":"1293","volume":"49","author":"T Shida","year":"2013","unstructured":"Shida T, Kato T, Tomita Y (2013) Comparison of preventive effect of hand-foot syndrome of multikinase inhibitor by applying urea ointment or heparinoid ointment. Nihon Byoin Yakuzai-shi 49:1293\u20131297 (in Japanese)","journal-title":"Nihon Byoin Yakuzai-shi"},{"key":"10902_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s12072-016-9774-x","volume":"11","author":"SM Lin","year":"2017","unstructured":"Lin SM, Lu SN, Chen PT et al (2017) HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. Hepatol Int 11:199\u2013208. https:\/\/doi.org\/10.1007\/s12072-016-9774-x","journal-title":"Hepatol Int"},{"key":"10902_CR15","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","volume":"71","author":"KK Miller","year":"2014","unstructured":"Miller KK, Gorcey L, McLellan BN (2014) Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 71:787\u2013794. https:\/\/doi.org\/10.1016\/j.jaad.2014.03.019","journal-title":"J Am Acad Dermatol"},{"key":"10902_CR16","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/annonc\/mdt541","volume":"25","author":"N Shinohara","year":"2014","unstructured":"Shinohara N, Nonomura N, Eto M et al (2014) A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma. Ann Oncol 25:472\u2013476. https:\/\/doi.org\/10.1093\/annonc\/mdt541","journal-title":"Ann Oncol"},{"key":"10902_CR17","doi-asserted-by":"publisher","first-page":"e038276","DOI":"10.1136\/bmjopen-2020-038276","volume":"10","author":"S Zenda","year":"2020","unstructured":"Zenda S, Ryu A, Takashima A et al (2020) Hydrocolloid dressing as a prophylactic use for hand\u2013foot skin reaction induced by multitargeted kinase inhibitors: protocol of a phase 3 randomised self-controlled study. BMJ Open 10:e038276. https:\/\/doi.org\/10.1136\/bmjopen-2020-038276","journal-title":"BMJ Open"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10902-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10902-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10902-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:45:28Z","timestamp":1784011528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10902-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10902"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10902-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was an intra-individual RCT, and the protocol was approved by the Japan Supportive, Palliative and Psychosocial Oncology Group (J-SUPPORT) under the designation J-SUPPORT1701, registered in December 2018 with the University Hospital Medical Information Network (UMIN000034853), and published as a protocol paper [\n                      \n                      ]. Approval was also obtained from the Clinical Research Review Board of the National Cancer Center Hospital (2018\u2013160).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Supplementary Fig.\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"A portion of this manuscript has already been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023, held from June 2 to June 6 in Chicago, Illinois.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous presentation"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"683"}}